GLP-1 Medications Ranked: Comparing Every Option in 2026

GLP-1 receptor agonists have transformed weight loss treatment. But there are now multiple options, and the differences between them matter. Here's how they compare based on published clinical data.

The Current Lineup

1. Tirzepatide (Zepbound/Mounjaro)
Type: Dual GIP/GLP-1 receptor agonist
Average weight loss: 20.9% at 15mg (SURMOUNT-1, 72 weeks)
Dosing: Weekly injection, titrated from 2.5mg to max 15mg
Brand cost: ~$1,000-1,100/month
Compounded cost: ~$97-200/month (where available)

Tirzepatide is the most effective approved weight loss medication by the data. The dual-agonist mechanism — activating both GIP and GLP-1 receptors — produces consistently higher weight loss than GLP-1-only drugs. SURMOUNT-5 confirmed this in a head-to-head against semaglutide.

2. Semaglutide (Wegovy/Ozempic)
Type: GLP-1 receptor agonist
Average weight loss: 14.9% at 2.4mg (STEP-1, 68 weeks)
Dosing: Weekly injection, titrated from 0.25mg to max 2.4mg
Brand cost: ~$1,300-1,400/month
Compounded cost: ~$150-350/month (where available)

Semaglutide was the first GLP-1 to produce dramatic weight loss in clinical trials. The STEP program enrolled over 10,000 participants across multiple trials and consistently showed 12-17% weight loss. It has the most real-world data of any current GLP-1 medication.

3. Liraglutide (Saxenda)
Type: GLP-1 receptor agonist
Average weight loss: 8.0% (SCALE trial, 56 weeks)
Dosing: Daily injection, titrated to 3.0mg
Brand cost: ~$1,400/month
Compounded cost: Less commonly compounded

Liraglutide was the pioneer — the first GLP-1 approved specifically for weight management. Its efficacy is lower than semaglutide and tirzepatide, and the daily injection is less convenient. It's still used, particularly for patients who've tried it and responded well, but it's no longer the first choice for new starts.

4. Oral Semaglutide (Rybelsus)
Type: GLP-1 receptor agonist (oral formulation)
Average weight loss: ~6-9% at 14mg (varies by trial)
Dosing: Daily pill, must be taken fasting with minimal water
Brand cost: ~$900-1,000/month

The oral formulation of semaglutide was a breakthrough for people who hate injections. The trade-off: lower bioavailability means less weight loss compared to injectable semaglutide. The fasting requirement is also inconvenient — you take it first thing in the morning with no more than 4oz of water, then wait 30 minutes before eating or drinking.

What's Coming

Retatrutide
Type: Triple agonist (GIP + GLP-1 + glucagon receptors)
Phase 3 trial weight loss: Up to 24.2% at 48 weeks in Phase 2
Status: Phase 3 trials ongoing, expected completion 2025-2026

Retatrutide adds a third mechanism — glucagon receptor activation — which increases energy expenditure (calorie burning) on top of the appetite suppression. Phase 2 data showed the highest weight loss of any anti-obesity medication ever tested. If Phase 3 confirms these results, it will likely become the new standard.

Orforglipron
Type: Oral non-peptide GLP-1 agonist
Phase 3 trial weight loss: ~14-15% at 36mg in Phase 2
Status: Phase 3 trials ongoing

Orforglipron is significant because it's an oral GLP-1 that achieves weight loss comparable to injectable semaglutide. Unlike oral semaglutide (Rybelsus), it doesn't require fasting and has better bioavailability. If approved, it would make GLP-1 therapy accessible without injections at meaningful efficacy levels.

How to Choose

The honest framing: all of these medications produce clinically meaningful weight loss. Even liraglutide's 8% average — the lowest on this list — represents significant health improvement. The "best" drug is the one you can actually get, afford, and tolerate.